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Objectives: On January 18, 2010, a part of the capital region of Denmark shifted the empirical
treatment of febrile conditions from cefuroxime to piperacillin/tazobactam. We compare empiri-
cal treatment with piperacillin/tazobactam versus cefuroxime for Escherichia coli bacteremia
with regard to 14 days mortality, in a low prevalence cohort of Extended-spectrum beta-
lactamase-producing E. coli.
Methods: From January 18, 2010 to December 31, 2012, we conducted a retrospective
cohort study including patients with E. coli bacteremia from six university hospitals in
Copenhagen, Denmark. Clinical and laboratory information was obtained from
a bacteremia research database, including information on comorbidity, and we used Cox
proportional hazard analysis to asses all-cause 14 days mortality.
Results: A total of 568 patients receiving either cefuroxime (n=377) or piperacillin/tazobactam
(n=191) as empirical therapy were included. In the Cox proportional hazard model, cefuroxime
treatment was signiﬁcantly associated with death (mortality rate ratio 3.95, CI 1.12–13.90). Other
variables associated with death were health care related infection (MRR 3.20, CI 1.67–6.15),
hospital-acquired infection (MRR 2,17, CI 1.02–4.62), admission at intensive care unit (MRR
20.45, 5.31–78.82), and combination therapy with ciproﬂoxacin (MRR 2.14, CI 0.98–4.68).
Conclusion: Empiric cefuroxime treatment of E. coli bacteremia was signiﬁcantly asso-
ciated with higher 14 days mortality in comparison with piperacillin/tazobactam.
Keywords: piperacillin/tazobactam, cefuroxime, E. coli, bacteremia, mortality
Introduction
Escherichia coli is a common pathogen causing infections in the urinary tract system and
the most frequent pathogen causing bacteremia in Denmark.1 Due to an increasing
frequency of Extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumo-
niae, a multidisciplinary intervention took place at the beginning of January 2010 in
Copenhagen, Denmark. One interventionwas to change the empirical treatment of febrile
conditions from cefuroxime ± gentamicin to piperacillin/tazobactam (PTZ) ±
gentamicin.2 Since PTZ is documented to be less selective for antimicrobial resistance
and therapeutically superior to cephalosporines against ESBLproducingE. coli, it is often
chosen to replace cefuroxime in the empirical treatment of febrile conditions.3–5 Most
E. coli strains inDenmark are susceptible to both cefuroxime and PTZ.To our knowledge,
there has never been a comparative study of cefuroxime and PTZ against E. coli
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bacteremia in a primarily susceptibleE. coli cohort. This study
aims to investigate the difference in mortality for patients with
E. coli bacteremia treated empirically with PTZ and cefurox-
ime, in a cohort of E. coli with a low prevalence of ESBL.
Materials and methods
Study setting
From January 18, 2010 to December 31, 2012, we con-
ducted a retrospective cohort study of E. coli bacteremia
patients from six hospitals in the capital region
of Denmark (total estimated population: 640,000);
Copenhagen University Hospital Hvidovre, Copenhagen
University Hospital Amager, Copenhagen University
Hospital Bispebjerg, Copenhagen University Hospital
Frederiksberg, Copenhagen University Hospital Glostrup
and Copenhagen University Hospital Bornholm. The hos-
pitals are all located in Copenhagen and work in collabora-
tion with the same population, and patients are exchanged
between the hospitals depending on capacity and specialty.
Personnel are widely exchanged, and some departments
service several hospitals. The hospitals in the capital
region of Denmark refer to the same antimicrobial guide-
lines, and all the included study hospitals use to the same
Department of Clinical Microbiology (DCM) at Hvidovre
Hospital. One of the hospitals, Copenhagen University
Hospital Bispebjerg (the intervention hospital), did not
use cefuroxime after January 18, 2010 due to the ESBL-
K. pneumoniae outbreak, and restricted the use of
ﬂuoroquinolones.2 We included patients who received
either cefuroxime or PTZ as empirical treatment, with or
without other antibiotics, typically gentamicin or cipro-
ﬂoxacin. Patients were excluded if they had received car-
bapenems or both PTZ and cefuroxime. Local guidelines
for dosage of the antibiotics were as follows: Cefuroxime
1.5 g q8h (GFR 10–50 mL/min: 1.5 g q12h or GFR
<10 mL/min: 1.5 g q24h); PTZ 4 g/0.5 g q8h (GFR
10–50 mL/min: 4 g/0.5 g q12h or GFR <10 mL/min:
4 g/0.5 g q24h); ciproﬂoxacin 400 mg q12h (GFR
<10 mL/min: 200 mg q12h); gentamicin 5 mg/kg q24h
following serum concentration measurements.
Microbiology and susceptibility testing
The six hospitals in the greater Copenhagen area are served
by the DCM at Copenhagen University Hospital Hvidovre.
Blood cultures were obtained when clinically indicated.
Culturing was obtained by a minimum of 30 mL of blood
per blood culture, either with two sets of two blood culture
bottles, using BacT/ALERT (bioMérieux, Marcy l’Étoile,
France) for ﬁve hospitals, or one set comprising three
bottles, using BACTEC (Becton-Dickinson, Sparks, MD,
USA) for one hospital. Antimicrobial susceptibility testing
was performed at the DCM with disc diffusion tests accord-
ing to EUCAST guidelines (www.EUCAST.org). All data
were recorded in a laboratory information system (ADBakt,
Autonik, Ramsta, Sweden).
Data source
Patients with E. coli bacteremia were identiﬁed in
ADBakt. The data were obtained from the Danish
Collaborative Bacteremia Network (DACOBAN), which
is a research database containing microbiological data
from positive blood cultures from three major clinical
microbiology departments in Denmark.6 Each positive
blood culture is linked to a unique civil registration num-
ber, given to all Danish residents. This unique number
enables DACOBAN to link the vital status (alive or date
of death), disappearance or emigration, of all patients from
the Danish Civil Registration System (CRS).7 The vital
status was obtained on September 27, 2013. Similarly,
DACODAN also extracts data on comorbidity based on
the Charlson Comorbidity Index (CCI) from the Danish
National Patient Registry (DNPR).8,9 The DNPR contains
hospital discharge diagnoses and surgical procedures from
all non-psychiatric inpatients since 1977. The information
obtained included date of admission, date of discharge,
and type of diagnosis (International Classiﬁcation of
Diseases, revision 10). Data on empirical antimicrobial
therapy were linked to DACODAN through the physi-
cians’ supplementary variables retrieved from electronic
databases at each department of microbiology.6
Deﬁnitions
E. coli bacteremia was deﬁned as any positive blood culture
with E. coli. Polymicrobial bacteremia was deﬁned as isola-
tion of another pathogenic microorganism from the blood
cultures. Resistant strains were deﬁned as any resistance to
cefpodoxime, PTZ, gentamicin or ciproﬂoxacin. A new posi-
tive blood culture >30 days after the initial positive blood
culture was deﬁned as a new episode and included as a new
case. Positive cultures obtained 48 hrs after admission were
classiﬁed as hospital-acquired, and within 48 hrs of admis-
sion, they were classiﬁed as community-acquired, except if
patients regularly visited the hospital (eg, HD or chemother-
apy) or had been hospitalized 30 days before and were
classiﬁed as health care related.10 CCI was calculated at the
Thønnings et al Dovepress
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time of hospitalization and was divided into three levels:
Low (a score of 0), medium (1–2), and high (≥3).8,11
Intensive care unit was deﬁned as admission to an intensive
care unit at the time of blood culturing. Empirical antibiotic
therapy was deﬁned as the antibiotic treatment given on
the day of blood culturing. Cefuroxime 1.5 g q8h and PTZ
4 g/0.5 g q8h was regarded as adequate empirical treatment,
unless the dosage was adjusted to the weight and/or kidney
function. Time to death was calculated from the day the ﬁrst
blood culture was drawn.
Statistical analysis
All the data are represented in medians and interquartiles.
Continuous variables were analyzed regarding normal dis-
tribution. Comparisons of independent normally distribu-
ted data were performed using the Student’s t-test. Non-
normally distributed data were compared using the Mann–
Whitney test and categorical data were analyzed with the
Fisher’s Exact test with odds ratios presented with 95%
conﬁdence intervals (CIs). We chose all-cause 14 days
mortality as an outcome, as we lacked information regard-
ing deﬁnitive antibiotic treatment. Cox proportional
hazards regression analysis was used to compute mortality
rate ratios (MRRs) with 95% CIs and survival curves. The
proportionality assumption was tested visually for catego-
rical variables and by Schoenfeld residuals for numerical
variables. The multivariate model was evaluated for con-
founders by stepwise excluding variables to detect changes
in the MRRs. The adjusted model was ﬁtted by excluding
variables that changed the MRR less than 0.1 points each
from the full model. The ﬁnal cox proportional hazard
model included treatment with cefuroxime, acquisition,
CCI, intensive care unit, intervention hospital, polymicro-
bial bacteremia and combination with ciproﬂoxacin. Two-
sided signiﬁcance was tested with the assumption of
P<0.05 as signiﬁcant. The statistical analysis was per-
formed by the Statistical Package for Social Sciences
(version 23.0; SPSS, IBM).
Ethical and data protection approval
The study was approved by the local ethics committee and
the Danish Data Protection Agency (no.: 03064, ID: AHH-
2014–012).
Results
A total of 707 patients with E. coli bacteremia were
identiﬁed (Figure 1). Of them 628 patients were treated
with either cefuroxime or PTZ. Six patients had
polymicrobial infections not covered with cefuroxime or
PTZ (one E. faecium, two M. morganii, and three
B. fragilis) and were excluded, as well as 54 patients
who did not receive an antibiotic to which the E. coli
isolate was susceptible. Hence, a total of 568 patients
with E. coli bacteremia remained.
Antimicrobial therapy
General characteristics of the E. coli bacteremia regard-
ing the empirical antibiotic treatment are summarized in
Table 1. Sixteen patients had polymicrobial bacteremia:
Six K. pneumoniae, three Proteus mirabilis, two
Klebsiella oxytoca, and one Streptococcus dysgalactiae,
all fully susceptible to both cefuroxime and PTZ. In the
last four cases, the other microbe present was
a coagulase-negative staphylococcus in all cases consid-
ered contaminations. Three children were in the cohort
(age 0, 8, and 16 years), and they were all treated with
cefuroxime. In no cases were both gentamicin and cipro-
ﬂoxacin administered. Cefuroxime treatment was signiﬁ-
cantly associated with combination therapy using
gentamicin (17.0% vs 9.9%, P=0.03), whereas PTZ treat-
ment was signiﬁcantly associated with combination ther-
apy with ciproﬂoxacin (24.9% vs 42.4%, P<0.01). There
was no signiﬁcant difference in the crude data regarding
mortality.
Differences between hospitals
Table 2 shows the differences between the intervention
hospital and the ﬁve other hospitals. The only signiﬁ-
cant differences were the empiric antibiotic therapy
with cefuroxime and combination with ciproﬂoxacin
(both P<0.01).
Mortality
Overall mortality in the cohort was 10.7% (67/628) 14 days
and 15.8% (99/628) 30 days after blood culturing. Table 3
shows the differences between non-survivors and survivors
on day 14. In the crude analysis, health care related (MRR
3.07, CI 1.59–5.92) and hospital acquisition (MRR 2.37, CI
1.11–5.04) as well as a high CCI (MRR 2.11, CI 1.02–4.39)
and intensive care unit (MRR 8.87, CI 1.75–44.93) were
signiﬁcantly associated with 14 days mortality.
Survival analysis
Included in the adjusted multivariate Cox regression model
were acquisition, CCI, intensive care unit, intervention hos-
pital, polymicrobial bacteremia, resistant strain, combination
Dovepress Thønnings et al
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with ciproﬂoxacin and treatment with cefuroxime (Table 3).
Signiﬁcant risk factors associated with death were a health
care related infection (MRR 3.20,
CI 1.67–6.15), hospital-acquired infection (MRR 2.17,
CI 1.02–4.62), admission at intensive care unit (MRR
20.45, 5.31–78.82), combination therapy with ciproﬂoxacin
(MRR 2.14, CI 0.98–4.68), and empiric antibiotic treatment
with cefuroxime (MRR 3.95, CI 1.12–13.90). Figure 2 shows
the individual survival curves for cefuroxime and PTZ treat-
ment based on the Cox proportional hazard model.
Subgroup analysis where strains resistant to ciproﬂoxacin
or gentamicin were excluded from the analyses did not alter
the results (data not shown). However, when excluding cases
where either ciproﬂoxacin or gentamicin was given as com-
bination therapy, MRR of empiric antibiotic treatment with
cefuroxime increased to 9.34 (CI 1.02–85.93, P=0.03).
Discussion
Our study shows that empiric antibiotic treatment of sus-
ceptible E. coli with cefuroxime leads to higher 14 days
mortality rates compared to PTZ. To our knowledge, this
is the ﬁrst time such a result has been reported for suscep-
tible E. coli.
Guidelines in study hospitals, except the intervention
hospital, reserved PTZ for more severe cases. At the inter-
vention hospital, a carbapenem would be used as a second
line drug instead. This difference in second line antibiotics
should be in favor of cefuroxime. Hence, we have reason to
believe that the difference we ﬁnd is conservative.
Furthermore, patients at the intervention hospital signiﬁ-
cantly more often received ciproﬂoxacin and were less likely
to receive gentamicin than the patients at the other hospitals.
Again, this should not act in favor of PTZ, since local guide-
lines stated that ﬂuoroquinolones, instead of gentamicin,
should only be added in case of septic shock.
Fluoroquinolones had in general been restricted to the treat-
ment of septic shock at the intervention hospital.2 This also
explains the association between combination therapy with
ciproﬂoxacin and death. Comparing cefuroxime and PTZ,
more female patients were treated with cefuroxime empiri-
cally, and gentamicin was more often given in combination
with cefuroxime. One explanation could be guidelines stating
Empirical treatment either 
cefuroxime or PTZ 
(n = 628)
Excluded (n = 60): 
- 6 patients with polymicrobial infections 
not covered with cefuroxime/PTZ. 
- 54 patients with E. coli isolate not 
susceptible to the given antibiotic. 
Included in the analysis 
(n = 568)
Treatment cefuroxime 
(n = 377)
Treatment PTZ 
(n = 191)
E. coli bacteremia 
(n = 707)
Excluded (n = 79): 
- 77 patients not treated with 
cefuroxime or PTZ empirically. 
- 2 patients treated with both 
cefuroxime and PTZ empirically. 
Figure 1 Flow diagram presenting the inclusion and exclusion procedure for patients with Escherichia coli (E. coli) bacteremia.
Abbreviation: PTZ, piperacillin/tazobactam.
Thønnings et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Infection and Drug Resistance 2019:121260
 
In
fe
ct
io
n 
an
d 
Dr
ug
 R
es
ist
an
ce
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
5.
17
8.
2 
on
 1
6-
Ju
l-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
cefuroxime and gentamicin should be used for a urinary tract
focus and females more often have a urinary tract infection.
Wewould expect a urinary tract focus to be relatively uncom-
plicated and a susceptible site for antibiotics to reach high
concentrations compared to an abdominal focus. Hence, this
should again be an advantage to cefuroxime. The subgroup
analysis excluding cases with combination therapy of cipro-
ﬂoxacin or gentamicin conﬁrmed these ﬁndings with
a further increasedMRR associated with cefuroxime therapy.
In Denmark, the incidence of ESBL producers in blood
culture positive E. coli has increased from 2% in 2003 to
9% in 2010,12 and has thereafter stabilized.1 Samples from
the primary health care who were forwarded to a DCM
showed an incidence of cefuroxime resistance at 6%.1
However, compared to some southern European countries
this is still a relatively low incidence. In our study, we
have shown a lower mortality rate when PTZ was admi-
nistered compared to cefuroxime despite the E. coli strains
being susceptible to cefuroxime. This result questions the
place of cefuroxime in the treatment of any severe E. coli
infection. A clinical randomized trial has previously
shown no difference in the outcome between PTZ and
cefuroxime/metronidazole in the treatment of intraabdom-
inal infections.13 In this study, there was a great diversity
in the bacterial strains, making it difﬁcult to extrapolate
the results in E. coli bacteremia. Recent studies concerned
with the treatment of E. coli infections have focused on the
challenges with more resistant strains, eg, ESBL produ-
cing E. coli.14,15 However, these studies do not provide
any information regarding cefuroxime treatment in
a susceptible population such as the present study.
Our ﬁndings could be related to differences in phar-
macokinetic and pharmacodynamic activity between the
drugs. It applies to beta lactams that the amount of time
the free concentration of the antibiotic exceeds the mini-
mal inhibitory concentration (fT >MIC) is the best phar-
macokinetic/pharmacodynamic predictor. Optimally
plasma drug concentration would be above MIC 50% of
the time. Both cefuroxime and piperacillin have clinical
breakpoints at MIC 8 mg/L.16 Usually cefuroxime is
administered 1.5 g q8h, which is also the case in this
cohort. Viberg et al, showed that 23% of E. coli infections
Table 1 Characteristics of Eshericha coli bacteremia cases regarding antimicrobial therapy from 2010 to 2012
All patients
(%)
Cefuroxime
(%)
Piperacillin/tazobactam
(%)
OR (95% CI) P-value
n=568 n=377 n=191
Age [median (25–75 percentiles)] 76 (62–84) 75 (61–84) 77 (62–84) 0.38
Gender (female) 318 (56.0) 220 (58.4) 98 (51.3) 1.33 (0.94–1.89) 0.13
Acquisition (n=503)
Community-acquired 331 (61.8) 211 (62.8) 100 (59.9) 1.00
Health care related 110 (21.9) 70 (20.8) 40 (24.0) 0.83 (0.53–1.31) 0.42
Hospital-acquired 82 (16.3) 55 (16.4) 27 (16.2) 1.04 (0.62–1.74) 0.89
Charlson Comorbidity Index
Low 157 (27.6) 105 (27.9) 52 (27.2) 1.00
Medium 207 (36.4) 143 (37.9) 64 (33.5) 1.11 (0.71–1.72) 0.66
High 204 (35.9) 129 (34.2) 75 (39.3) 0.85 (0.55–1.32) 0.47
Intensive care unit 6 (1.1) 3 (0.8) 3 (1.6) 0.50 (0.10–2.51) 0.41
Intervention hospital 175 (30.8) 7 (1.9) 168 (88.0) 0.003
(0.001–0.006)
<0.01
Polymicrobial bacteraemia (n=503) 16 (3.2) 9 (2.3) 7 (4.2) 0.65 (0.24–1.78) 0.43
Resistant strain 38 (6.7) 21 (5.6) 17 (8.9) 0.60 (0.31–1.17) 0.16
Combination therapy with
gentamicin
83 (14.6) 64 (17.0) 19 (9.9) 1.85 (1.07–3.19) 0.03
Combination therapy with
ciproﬂoxacin
175 (30.8) 94 (24.9) 81 (42.4) 0.45 (0.31–0.65) <0.01
14 days mortality 60 (10.6) 45 (11.9) 15 (7.9) 1.5 (0.86–2.93) 0.09
30 days mortality 88 (15.5) 61 (16.2) 27 (14.1) 1.17 (0.72–1.92) 0.31
Note: P<0.05 shown in bold.
Dovepress Thønnings et al
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did not reach the target T>MIC 50% for wild-type dis-
tribution MIC, when using 1.5 g q8h at creatinine clear-
ance (CLcr) >80 mL/min.17 Carlier et al, reported
similarly that 1.5 g q8h did not reach their target MIC
8 mg/L in critically ill patients when CLcr≥50 mL/min.18
Both studies reported the need for a shorter dosing inter-
val with increased CLcr. Patients with sepsis are likely to
have an increased CLcr, as a response to treatment.19 One
approach could be to increase the regime to cefuroxime
1.5 g q6h for patients with a normal kidney function.
Another possible solution is continuous infusion. We do
not know whether the difference in mortality between
PTZ and cefuroxime is related speciﬁcally to cefuroxime
or cephalosporins as a class. Further studies are required.
The study has several strengths. It is based on a large
population and all included data are highly validated.
Furthermore, we had a high statistical precision, indicated
by the relatively narrow CIs. Our study, however, also has
some important limitations that should be taken into consid-
eration. Firstly, the study design was observational, which in
contrast to randomized clinical trials has a risk of confound-
ing by indication when evaluating treatment; we do not know
if the physician systematically treated one category of
patients with cefuroxime and another category with a PTZ.
However, only gender and antibiotic treatment showed sig-
niﬁcant differences between the two groups. Secondly, the
intervention hospital was responsible for 88% of the cases
with PTZ treatment. Therefore, there could be a risk that the
difference between the drugs was a difference between the
hospitals. As demonstrated in Table 2, nothing indicated that
there was a difference in the populations between the inter-
vention hospital and the other study hospitals. As previously
described, the hospitals work in collaboration were patients
and personnel are exchanged and the hospitals use the same
guidelines. This makes the hospitals comparable, and the
difference in the physical site does not explain the difference
we found. Thirdly, information regarding deﬁnitive antibiotic
therapy was missing. We took this into consideration by
investigating 14 days mortality instead of 30 days mortality.
However, when the empirical treatment is evaluated to be
adequate and in line with local guidelines, it is likely to be
continued and therefore be identical with the deﬁnitive treat-
ment. Hence, in most of these cases, the empirical and
deﬁnitive treatment would be the same although we cannot
document this. Fourthly, the study lacked information regard-
ing the anatomic focus of the infection and the severity of the
Table 2 Characteristics of E. coli bacteremia cases regarding hospitals from 2010 to 2012
Intervention hospital (%) Other hospitals (%) OR (95% CI) P-value
n=175 n=393
Age [median (25–75 percentiles)] 77 (64–84) 75 (61–84) 0.24
Gender (female) 92 (52.6) 226 (57.5) 0.82 (0.57–1.17) 0.31
Acquisition (n=553)
Community-acquired 96 (63.2) 215 (61.3) 1.00
Health care related 34 (22.4) 76 (21.7) 1.00 (0.63–1.61) 0.99
Hospital-acquired 22 (14.5) 60 (17.1) 0.82 (0.48–1.42) 0.48
Charlson Comorbidity Index
Low 45 (25.7) 112 (28.5) 1.00
Medium 61 (34.9) 146 (37.2) 0.96 (0.61–1.52) 0.87
High 69 (39.4) 135 (34.4) 1.27 (0.81–2.00) 0.30
Intensive care unit 1 (0.6) 5 (1.3) 0.45 (0.05–3.85) 0.67
Polymicrobial bacteraemia (n=503) 8 (5.3) 8 (2.0) 2.25 (0.83–6.08) 0.17
Resistant strain 15 (8.6) 23 (5.9) 1.51 (0.77–2.97) 0.28
Combination with gentamicin 19 (10.9) 64 (16.3) 0.63 (0.36–1.08) 0.10
Combination with ciproﬂoxacin 68 (38.9) 107 (27.2) 1.70 (1.17–2.48) <0.01
Treatment with cefuroxime 7 (4.0) 370 (94.1) 0.003 (0.001–0.006) <0.01
14 days mortality 14 (8.0) 46 (11.7) 0.66 (0.35–1.23) 0.24
30 days mortality 24 (13.7) 64 (16.3) 0.82 (0.49–1.36) 0.46
Note: P<0.05 shown in bold.
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bacteremia at onset. Yet, as previously described we would
expect PTZ more often to be given in case of a difﬁcult
anatomic focus and in more severe cases. Therefore, this
lack of information could underestimate the difference
between PTZ and cefuroxime treatment.
In conclusion, empirical treatment with cefuroxime of
E. coli bacteremia in a low ESBL cohort was signiﬁcantly
associated with a higher mortality than PTZ.
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Figure 2 Cox regression survival curves for 14-day survival after antibiotic treat-
ment onset.
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